The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

Detailed price information for KKR & Company LP (KKR-N) from The Globe and Mail including charting and trades.

Q2 2025 Management View Co-CEO Scott C. Nuttall highlighted the company's strong performance, stating that fee-related earnings per share reached $0.98, total operating earnings were $1.33 per share, ...

KKR executives said strong momentum in their business gave them confidence on Thursday of beating earnings targets for 2026, ...

Investment giant KKR reported a 9% rise in adjusted net income for the second quarter on Thursday, bolstered by an increase ...

KKR plows deeper into industry with HealthCare Royalty Partners investment; Why Vinay Prasad resigned from the FDA after less than three months; Indie scientific groups step into the gap for ...

The firm brought in $1.6 billion from outside investors for its fifth main growth fund and separately promoted dealmaker Sri Rao. The credit-card company reported increases in profit and sales in the ...

As part of the transaction, HCRx Chairman and CEO Clarke Futch will continue to lead the HCRx team and will maintain an ongoing substantial minority interest in HCRx.

KKR’s deal is a bet that financing needs from drug companies will continue to rise. - Michael Nagle/Bloomberg News. KKR has ...

Investment firm KKR (KKR) announced on Wednesday the acquisition of a majority stake in the biopharma royalty acquisition company, HealthCare Royalty Partners.

KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in ...